古巴艾滋病毒/艾滋病患者对抗逆转录病毒药物的不良反应。

IF 1.8 4区 医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Medicc Review Pub Date : 2021-04-01 Epub Date: 2021-04-30 DOI:10.37757/MR2021.V23.N2.7
Mayasil Morales-Pérez
{"title":"古巴艾滋病毒/艾滋病患者对抗逆转录病毒药物的不良反应。","authors":"Mayasil Morales-Pérez","doi":"10.37757/MR2021.V23.N2.7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Disease and deaths from HIV/AIDS have decreased since antiretroviral treatment was introduced in 1996. Since 2005, as treatment availability has increased worldwide, deaths from HIV/AIDS have declined 48%. As of November 2019, 26,952 cases have been reported in Cuba, of which 5159 (19.1%) are deceased. The country has experienced a reduction in mortality rates since 2002, when antiretroviral treatment became available. Although there are clearly benefits to treatment, it is important to understand antiretroviral safety profiles as their toxicity may lower treatment adherence.</p><p><strong>Objective: </strong>Describe adverse reactions attributable to antiretrovirals used in Cuban patients living with HIV/AIDS.</p><p><strong>Methods: </strong>I studied notifications of adverse reactions to antiretrovirals used in Cuban patients with HIV/AIDS from January 2003 to December 2017. The sample consisted of 352 notifications in the National Pharmacovigilance Database regarding adverse reactions attributed to antiretrovirals. The variables considered were sex, notification year, antiretroviral drug, and number, type, frequency and severity of adverse reactions, whether or not they were preventable, and the reasons for categorizing them as they were.</p><p><strong>Results: </strong>Antiretrovirals reported an average adverse reaction rate of 2.1 per million population per year, representing 24.2% of adverse reactions produced by the antiviral drug group in that period. Adult males represented 75% (264/352) of patients who had adverse reactions to antiretrovirals. Most adverse reactions were in response to nevirapine (29.0%; 102/352) and zidovudine (26.7%; 94/352). The most frequent reactions were hypersensitivity (24.4%; 86/352), digestive disorders (15.9%; 56/352) and anemia (15.6%; 55/352). Reactions were common (62.5%; 220/352) and moderate in severity (70.4%; 248/352). Preventable reactions made up 52.6% (185/352) of adverse reactions. Of preventable reactions, 68.1% (126/185) were associated with drug interactions and 16.2% (30/185) with improper dosage or prescription errors.</p><p><strong>Conclusions: </strong>Adverse reactions to antiretrovirals in Cuban patients are common and moderate in severity. The drug with the most notifications was nevirapine, and the most common adverse reaction was hypersensitivity. More than half of adverse reactions are considered preventable, and their main causes are prescription errors.</p>","PeriodicalId":49835,"journal":{"name":"Medicc Review","volume":"23 2","pages":"21"},"PeriodicalIF":1.8000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Adverse Reactions to Antiretrovirals in Cuban Patients Living with HIV/AIDS.\",\"authors\":\"Mayasil Morales-Pérez\",\"doi\":\"10.37757/MR2021.V23.N2.7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Disease and deaths from HIV/AIDS have decreased since antiretroviral treatment was introduced in 1996. Since 2005, as treatment availability has increased worldwide, deaths from HIV/AIDS have declined 48%. As of November 2019, 26,952 cases have been reported in Cuba, of which 5159 (19.1%) are deceased. The country has experienced a reduction in mortality rates since 2002, when antiretroviral treatment became available. Although there are clearly benefits to treatment, it is important to understand antiretroviral safety profiles as their toxicity may lower treatment adherence.</p><p><strong>Objective: </strong>Describe adverse reactions attributable to antiretrovirals used in Cuban patients living with HIV/AIDS.</p><p><strong>Methods: </strong>I studied notifications of adverse reactions to antiretrovirals used in Cuban patients with HIV/AIDS from January 2003 to December 2017. The sample consisted of 352 notifications in the National Pharmacovigilance Database regarding adverse reactions attributed to antiretrovirals. The variables considered were sex, notification year, antiretroviral drug, and number, type, frequency and severity of adverse reactions, whether or not they were preventable, and the reasons for categorizing them as they were.</p><p><strong>Results: </strong>Antiretrovirals reported an average adverse reaction rate of 2.1 per million population per year, representing 24.2% of adverse reactions produced by the antiviral drug group in that period. Adult males represented 75% (264/352) of patients who had adverse reactions to antiretrovirals. Most adverse reactions were in response to nevirapine (29.0%; 102/352) and zidovudine (26.7%; 94/352). The most frequent reactions were hypersensitivity (24.4%; 86/352), digestive disorders (15.9%; 56/352) and anemia (15.6%; 55/352). Reactions were common (62.5%; 220/352) and moderate in severity (70.4%; 248/352). Preventable reactions made up 52.6% (185/352) of adverse reactions. Of preventable reactions, 68.1% (126/185) were associated with drug interactions and 16.2% (30/185) with improper dosage or prescription errors.</p><p><strong>Conclusions: </strong>Adverse reactions to antiretrovirals in Cuban patients are common and moderate in severity. The drug with the most notifications was nevirapine, and the most common adverse reaction was hypersensitivity. More than half of adverse reactions are considered preventable, and their main causes are prescription errors.</p>\",\"PeriodicalId\":49835,\"journal\":{\"name\":\"Medicc Review\",\"volume\":\"23 2\",\"pages\":\"21\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2021-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicc Review\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.37757/MR2021.V23.N2.7\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/4/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicc Review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.37757/MR2021.V23.N2.7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 3

摘要

导言:自1996年引入抗逆转录病毒治疗以来,艾滋病毒/艾滋病的发病率和死亡率有所下降。自2005年以来,随着世界范围内治疗的增加,艾滋病毒/艾滋病死亡人数下降了48%。截至2019年11月,古巴共报告26952例病例,其中5159例(19.1%)死亡。自2002年开始提供抗逆转录病毒治疗以来,该国的死亡率有所下降。虽然治疗有明显的益处,但了解抗逆转录病毒的安全性概况很重要,因为它们的毒性可能降低治疗的依从性。目的:描述古巴艾滋病毒/艾滋病患者使用抗逆转录病毒药物的不良反应。方法:研究2003年1月至2017年12月古巴HIV/AIDS患者使用抗逆转录病毒药物不良反应的通报情况。样本包括国家药物警戒数据库中有关抗逆转录病毒药物不良反应的352份通报。考虑的变量包括性别、通报年份、抗逆转录病毒药物、不良反应的数量、类型、频率和严重程度、它们是否可以预防以及将它们分类的原因。结果:抗逆转录病毒药物报告的平均不良反应发生率为2.1 /百万人/年,占同期抗病毒药物组不良反应的24.2%。对抗逆转录病毒药物有不良反应的患者中,成年男性占75%(264/352)。不良反应以奈韦拉平为主(29.0%;102/352)和齐多夫定(26.7%;94/352)。最常见的反应是过敏(24.4%;86/352),消化系统疾病(15.9%;56/352)和贫血(15.6%;55/352)。反应常见(62.5%;220/352)和中度(70.4%;248/352)。可预防反应占不良反应的52.6%(185/352)。在可预防的反应中,68.1%(126/185)与药物相互作用有关,16.2%(30/185)与剂量不当或处方错误有关。结论:古巴患者对抗逆转录病毒药物的不良反应很常见,严重程度中等。通报最多的药物是奈韦拉平,最常见的不良反应是过敏反应。一半以上的不良反应被认为是可以预防的,其主要原因是处方错误。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Adverse Reactions to Antiretrovirals in Cuban Patients Living with HIV/AIDS.

Introduction: Disease and deaths from HIV/AIDS have decreased since antiretroviral treatment was introduced in 1996. Since 2005, as treatment availability has increased worldwide, deaths from HIV/AIDS have declined 48%. As of November 2019, 26,952 cases have been reported in Cuba, of which 5159 (19.1%) are deceased. The country has experienced a reduction in mortality rates since 2002, when antiretroviral treatment became available. Although there are clearly benefits to treatment, it is important to understand antiretroviral safety profiles as their toxicity may lower treatment adherence.

Objective: Describe adverse reactions attributable to antiretrovirals used in Cuban patients living with HIV/AIDS.

Methods: I studied notifications of adverse reactions to antiretrovirals used in Cuban patients with HIV/AIDS from January 2003 to December 2017. The sample consisted of 352 notifications in the National Pharmacovigilance Database regarding adverse reactions attributed to antiretrovirals. The variables considered were sex, notification year, antiretroviral drug, and number, type, frequency and severity of adverse reactions, whether or not they were preventable, and the reasons for categorizing them as they were.

Results: Antiretrovirals reported an average adverse reaction rate of 2.1 per million population per year, representing 24.2% of adverse reactions produced by the antiviral drug group in that period. Adult males represented 75% (264/352) of patients who had adverse reactions to antiretrovirals. Most adverse reactions were in response to nevirapine (29.0%; 102/352) and zidovudine (26.7%; 94/352). The most frequent reactions were hypersensitivity (24.4%; 86/352), digestive disorders (15.9%; 56/352) and anemia (15.6%; 55/352). Reactions were common (62.5%; 220/352) and moderate in severity (70.4%; 248/352). Preventable reactions made up 52.6% (185/352) of adverse reactions. Of preventable reactions, 68.1% (126/185) were associated with drug interactions and 16.2% (30/185) with improper dosage or prescription errors.

Conclusions: Adverse reactions to antiretrovirals in Cuban patients are common and moderate in severity. The drug with the most notifications was nevirapine, and the most common adverse reaction was hypersensitivity. More than half of adverse reactions are considered preventable, and their main causes are prescription errors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medicc Review
Medicc Review PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
3.30
自引率
9.50%
发文量
49
审稿时长
>12 weeks
期刊介绍: Uphold the highest standards of ethics and excellence, publishing open-access articles in English relevant to global health equity that offer the best of medical, population health and social sciences research and perspectives by Cuban and other developing-country professionals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信